Search - tctmd.com

Displaying 141 - 160 of 254

Sort: Relevancy | Date

News Conference News ACC 2019

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

Michael O'Riordan

March 25, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

Shelley Wood

March 01, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Features

Top News in Heart Failure: 2018

Shelley Wood

December 28, 2018

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

Michael O'Riordan

November 11, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

Caitlin E. Cox

October 31, 2018

News Daily News

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Caitlin E. Cox

May 16, 2018

News Conference News SCAI 2018

Coronary Plaques in Psoriasis Patients Change After Treatment With Biologics

L.A. McKeown

May 01, 2018

News Daily News

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

Shelley Wood

April 18, 2018

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

News Conference News ACC 2018

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

Michael O'Riordan

March 12, 2018

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Shelley Wood

March 05, 2018

News Daily News

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Michael O'Riordan

January 02, 2018

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

News Daily News

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

Michael O'Riordan

October 20, 2017

News Opinion Editor's Corner ESC 2017

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

Shelley Wood

September 08, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

Advertisement

PIONEER-HF Extension Study Further Supports Starting Sacubitril/Valsartan in the Hospital

TCTMD’s Top 10 Most Popular Stories for February 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Top News in Heart Failure: 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

PIONEER-HF: Sacubitril/Valsartan Safe and Effective in Acute Decompensated Heart Failure

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

ESC Consensus Statement Tackles Inflammation, Cholesterol Connection in a Post-CANTOS World

Coronary Plaques in Psoriasis Patients Change After Treatment With Biologics

Silent MI Often Precedes Acute MI, Portends Worse Patient Outcomes

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Canakinumab Falls Short of Halting Progression to Diabetes in Patients at Risk: CANTOS

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Colchicine Stabilizes Plaque in ACS Patients, Imaging Study Suggests

My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content